Skip to content
Wockhardt
  • Home
  • About Us
    • Chairman’s Profile
    • Board Of Directors
    • Team Wockhardt
    • Corporate Milestones
    • Research & Development
      • R&D at Wockhardt
      • New Drug Discovery
        • Pipeline / Projects
        • News & Events
        • Publications
          • ZAYNICH®
          • WCK 4873
          • WCK 4282
          • WCK 6777
      • Biologicals
        • News & Events
        • Pipeline / Projects
        • Publications
      • R&D Contact
    • Our Manufacturing Units
      • Shendra, India
      • Biotech Park, India
      • Daman, India
      • Ankleshwar, India
    • Global Footprint
      • India
      • UK & Europe
      • Emerging Markets
    • Products
      • India Branded Business
      • API
      • Russia – CIS
      • UK
      • Irish Market
      • Emerging Markets
      • Quality Generics
    • Quality Policy
  • Investors
    • From Chairman’s Office
      • AGM Speech
      • Letter to Shareowners
    • Financials
      • Annual Report
      • Quarterly Results
      • Financial Press Releases
      • Related Party Transactions
    • Subsidiary Financials
    • Annual Return
    • Corporate Governance
      • Policies & Codes
      • Committee’s of the Board
      • Familiarisation programs
      • Shareholding Pattern
      • Secretarial Compliance Report
      • Authorised KMP
      • Corporate Actions
      • Memorandum of Association and Article of Association
      • ESOP Scheme
      • Disclosures under Regulation 46 of SEBI LODR Regulations
    • Announcements / Disclosures
    • Shareholders Meeting / Postal ballot
      • AGM Notice
      • Proceedings
      • Voting Results
      • Transcript of the AGM
    • IEPF
      • Unclaimed Dividend
      • Nodal Officer
    • Analyst/ Investors
      • Presentation
      • Audio / Video Recording
      • Transcript
    • Shareowner Services
      • FAQ
      • Green Initiative
      • Investor Contact
      • Other Notices
      • Credit Rating
  • careers
    • Introduction
    • Life@Wockhardt
    • L&D Initiatives
    • Voice of Wockhardians
    • Career@Wockhardt
  • Media
    • Press Releases
    • Wockhardt in Media
  • ESG
  • Contact us

Home / Investor / Page 184

Archives: Investor

This post type contains { $postTypeName } information

FINANCIAL RESULTS FY9 Q4

For the Quarter Ended 31st December, 2009

Wockhardt launches anti – hypertensive drug Nicardipine injections in USA

QUARTERLY Reports (Q3)

FINANCIAL RESULTS FY9 Q3

Wockhardt receives US FDA approval for Prostate drug Alfuzosin tablets

For the Quarter Ended 30th September, 2009

Wockhardt receives US FDA approval for Prostate drug Tamsulosin capsules

Wockhardt wins Government of India Patent Award

Wockhardt divests its Veterinary business to Vetoquinol

Posts navigation

Previous page Page 1 … Page 183 Page 184 Page 185 … Page 191 Next page

Recent Posts

  • Hello world!

Recent Comments

  • A WordPress Commenter on Hello world!

Archives

  • June 2018

Categories

  • account of subs
  • AGM
  • AGM Notice
  • Analyst / Investors
  • Announcements or Disclosures
  • annual reports
  • Annual Return
  • Attendance slip
  • Audio Video Recording
  • Chairman_s Agm Speeches
  • Chairman_s Letter
  • Committee's of the Board
  • Corporate Actions
  • Credit Rating
  • Details of Unclaimed Dvidends
  • Familiarisation programs
  • FAQ
  • Filing with Stock Exchange
  • Financial Press Releases
  • Financials at a glance
  • Investor Communication
  • Investor Meet
  • Media Coverage
  • Newspaper AD
  • Other Shareholder Services
  • Policies
  • Presentation
  • Press Release
  • Proceedings
  • Quarterly Reports
  • Relater Party Transactions
  • Secretarial Compliance Report
  • Shareholding Pattern
  • Statutory Communication
  • Subsidiary Financials
  • Transcript
  • Transcript of the AGM
  • Transfer of Shares to IEPF
  • Uncategorized
  • Voting Results

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • About Us
    • Chairman’s Profile
    • Board Of Directors
    • Team Wockhardt
    • Corporate Milestones
    • Research & Development
      • R&D at Wockhardt
      • New Drug Discovery
        • Pipeline / Projects
        • News & Events
        • Publications
          • ZAYNICH®
          • WCK 4873
          • WCK 4282
          • WCK 6777
      • Biologicals
        • News & Events
        • Pipeline / Projects
        • Publications
      • R&D Contact
    • Our Manufacturing Units
      • Shendra, India
      • Biotech Park, India
      • Daman, India
      • Ankleshwar, India
    • Global Footprint
      • India
      • UK & Europe
      • Emerging Markets
    • Products
      • India Branded Business
      • API
      • Russia – CIS
      • UK
      • Irish Market
      • Emerging Markets
      • Quality Generics
    • Quality Policy
  • Investors
    • From Chairman’s Office
      • AGM Speech
      • Letter to Shareowners
    • Financials
      • Annual Report
      • Quarterly Results
      • Financial Press Releases
      • Related Party Transactions
    • Subsidiary Financials
    • Annual Return
    • Corporate Governance
      • Policies & Codes
      • Committee’s of the Board
      • Familiarisation programs
      • Shareholding Pattern
      • Secretarial Compliance Report
      • Authorised KMP
      • Corporate Actions
      • Memorandum of Association and Article of Association
      • ESOP Scheme
      • Disclosures under Regulation 46 of SEBI LODR Regulations
    • Announcements / Disclosures
    • Shareholders Meeting / Postal ballot
      • AGM Notice
      • Proceedings
      • Voting Results
      • Transcript of the AGM
    • IEPF
      • Unclaimed Dividend
      • Nodal Officer
    • Analyst/ Investors
      • Presentation
      • Audio / Video Recording
      • Transcript
    • Shareowner Services
      • FAQ
      • Green Initiative
      • Investor Contact
      • Other Notices
      • Credit Rating
  • careers
    • Introduction
    • Life@Wockhardt
    • L&D Initiatives
    • Voice of Wockhardians
    • Career@Wockhardt
  • Media
    • Press Releases
    • Wockhardt in Media
  • ESG
  • Contact us

Quick Links

  • Home
  • About Us
  • Investors
  • Careers
  • Media
  • ESG
  • Contact Us
  • Pharmacovigilance – Adverse Event Reporting
  • Privacy Policy
  • Archival Policy
  • Terms and Conditions

Get in Touch

D-4 MIDC, Chikalthana
Chhatrapati Sambhajinagar, 431006, India
91-22-2653 4444
contactus@wockhardt.com
Corporate Identity Number: L24230MH1999PLC120720

Wock Stock

wpChatIcon